Passage Bio, Inc. (PASG)
| Market Cap | 16.55M -18.3% |
| Revenue (ttm) | n/a |
| Net Income | -37.68M |
| EPS | -11.84 |
| Shares Out | 3.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,947 |
| Open | 5.21 |
| Previous Close | 5.36 |
| Day's Range | 5.06 - 5.38 |
| 52-Week Range | 3.94 - 20.00 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | 14.00 (+171.32%) |
| Earnings Date | May 12, 2026 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PASG stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 171.32% from the latest price.
News
Wedbush downgrades Passage Bio to Neutral on regulatory uncertainties
As previously reported, Wedbush analyst Yun Zhong downgraded Passage Bio (PASG) to Neutral from Outperform with a price target of $8, down from $32. The firm cites Monday’s regulatory update…
Passage Bio downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Yaron Werber downgraded Passage Bio (PASG) to Hold from Buy with no price target after the company released updated Phase 1/2 frontotemporal dementia with granulin mutations data…
Passage Bio price target lowered to $15 from $30 at Oppenheimer
Oppenheimer lowered the firm’s price target on Passage Bio (PASG) to $15 from $30 and keeps an Outperform rating on the shares after the company released upliFT-D data alongside FDA…
Passage Bio downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Passage Bio (PASG) to Neutral from Outperform with a price target of $8, down from $32.
Passage Bio downgraded to Neutral from Buy at Chardan
Chardan analyst Janani Sundararajan downgraded Passage Bio (PASG) to Neutral from Buy with a $7 price target following the company’s decision to pursue strategic alternatives. The firm sees uncertaint...
Passage Bio downgraded to Neutral from Buy at Lucid Capital
Lucid Capital analyst Elemer Piros downgraded Passage Bio (PASG) to Neutral from Buy with a price target of $9, down from $68, after the company reported updated data from the…
Passage Bio reports updated interim data from upliFT-D trial
Passage Bio (PASG) reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia, FTD, with granulin mutations. In addition, t...
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
Passage Bio initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Passage Bio (PASG) with an Outperform rating and $30 price target. The firm views the year-to-date pullback in shares as “an overreaction” to competitor program failu...
Passage Bio Transcript: TD Cowen 46th Annual Health Care Conference
AAV gene therapy for FTD-GRN is advancing with a focus on earlier-stage patients and a safer, lower dose, showing promising biomarker and safety data. Regulatory discussions are ongoing, and a Huntington’s program is progressing toward clinical candidate selection.
Passage Bio price target lowered to $23 from $67 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Passage Bio (PASG) to $23 from $67 and keeps a Buy rating on the shares. The firm updated it model…
Passage Bio reports Q4 EPS ($4.09), consensus ($2.80)
“We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia,” said Will Chou, M.D.,…
Passage Bio sees cash runway through 1Q27
Cash and cash equivalents were $46.3 million as of December 31, 2025, as compared to cash, cash equivalents, and marketable securities of $76.8 million as of December 31, 2024. The…
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety...
Passage Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Lead gene therapy program for FTD-GRN shows robust, durable target engagement and favorable safety, with a focus on earlier-stage patients and improved trial design. Huntington's program targets MSH3, with clinical candidate selection expected in H2. Cash runway extends into Q1 2027.
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio initiated with a Buy at Lucid Capital
Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio (PASG) with a Buy rating and $68 price target Passage Bio, which has developed a one-time gene therapy treatment, PBFT02,…
Passage Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The lead gene therapy program targets early-stage FTD-GRN patients, aiming to raise progranulin levels more effectively than competitors. Encouraged by FDA guidance, the team plans early regulatory engagement and expects key data and feedback in the first half of next year.
Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)
“We are pleased to report that we have opened enrollment in our third FTD-GRN and first FTD-C9orf72 patient cohorts in our ongoing upliFT-D clinical trial of PBFT02. We recognize the…
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comp...
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Gene therapy programs for neurodegenerative diseases are advancing with local delivery, AI-driven data analysis, and strong clinical results. Regulatory agencies are increasingly flexible, and access is expected to improve as procedures align with existing hospital practices.
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
PBFT02, a one-time AAV1 gene therapy for FTD, shows robust, durable increases in progranulin and early signs of slowing neurodegeneration, with a favorable safety profile and strong competitive positioning. Expansion to new patient groups and key regulatory milestones are planned through 2026.
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...